R&D News | pharmaphorum

News

Sutro has shelved its lead drug for ovarian cancer and turned its attention to three preclinical candidates in a major shake-up of its business.

News

Amgen is preparing to file a third indication for Uplizna, as a twice-yearly therapy for generalised myasthenia gravis, following new phase 3 data.

News

Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery operations.

News

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.

News

Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.

News

Lila Sciences has emerged with $200m in seed financing to advance its vision of AI-powered, fully autonomous labs to power scientific advances.